Computed Tomography Assisted Biopsy

PROCEDURE3 trials

Sponsors

National Cancer Institute (NCI), Roswell Park Cancer Institute, Jonsson Comprehensive Cancer Center

Conditions

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Extramedullary Disease in Multiple MyelomaLung AdenocarcinomaLung CancerMetastatic Gastric Adenocarcinoma

Early Phase 1

Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

RecruitingNCT07235280

Jonsson Comprehensive Cancer CenterLung Adenocarcinoma, Stage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8, Stage IA2 Lung Cancer AJCC v8 +2

Start: 2025-12-02End: 2029-06-29Target: 48Updated: 2026-02-19

Phase 2

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Active, not recruitingNCT03641313

National Cancer Institute (NCI)Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8 +5

Start: 2020-11-16End: 2027-01-28Updated: 2026-07-30

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

RecruitingNCT06627751

Roswell Park Cancer InstituteExtramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma

Start: 2025-05-01End: 2030-05-01Target: 28Updated: 2026-08-18

Related Papers

NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer.

2025-12-01

A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer.

Journal of Clinical Oncology2023-06-014 citations

Abstract P032: Berzosertib plus irinotecan in patients with TP53 mutant gastric/gastroesophageal junction adenocarcinoma: A phase II study

Molecular Cancer Therapeutics2021-12-01

A phase II study of M6620 and irinotecan in TP53 mutant gastric and gastroesophageal junction (GEJ) adenocarcinoma patients (pts) [NCT03641313].

Journal of Clinical Oncology2019-01-291 citations